Adderall News and Research RSS Feed - Adderall News and Research

Adderall (dextroamphetamine-amphetamine) is a combination of two synthetic agents with central nervous system stimulant activity. Both agents are non-catecholamine, sympathomimetic agents that elevate blood pressure and cause bronchodilation. These agents are commonly abused psychostimulant drugs that induce psychologic dependence manifested by elevated mood, increased wakefulness, concentration, physical performance and a feeling of well-being. Tolerance to various effects develops unequally, so that tachycardia and enhanced alertness diminish while psychotoxic effects (hallucinations and delusions) may occur.
Shire signs agreement to supply authorized generic version of Adderall XR

Shire signs agreement to supply authorized generic version of Adderall XR

Shire plc, announces that its subsidiary Shire US Inc. has entered into an agreement to supply an authorized generic version of its product Adderall XR. [More]
State highlights: Calif. Gov. Vetoes 'biosimilars' bill; health data gateway opens in Calif.; L.A. health workers required to get flu shots

State highlights: Calif. Gov. Vetoes 'biosimilars' bill; health data gateway opens in Calif.; L.A. health workers required to get flu shots

A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs. [More]
First Edition: October 16, 2013

First Edition: October 16, 2013

Today's headlines including stories detailing how certain health law provisions are factoring in to the continuing congressional budget stalemate. [More]
Shire resolves patent infringement lawsuit against Teva relating to INTUNIV tablet

Shire resolves patent infringement lawsuit against Teva relating to INTUNIV tablet

Shire LLC has settled its litigation against Teva Pharmaceuticals USA Inc. ("Teva") in connection with Teva's Abbreviated New Drug Application ("ANDA") for a generic version of Shire's INTUNIV (guanfacince) Extended Release Tablets for the treatment of Attention Deficit Hyperactivity Disorder. [More]
New U-M poll shows 1 in 100 parents believe their kids use prescription stimulants to boost grades

New U-M poll shows 1 in 100 parents believe their kids use prescription stimulants to boost grades

As high schoolers prepare for final exams, teens nationwide may be tempted to use a "study drug" -- a prescription stimulant or amphetamine -- to gain an academic edge. But a new University of Michigan poll shows only one in 100 parents of teens 13-17 years old believes that their teen has used a study drug. [More]
Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Shire plc, the global specialty biopharmaceutical company, announces that it will present scientific data in 7 poster presentations at the American Psychiatric Association 166th Annual Meeting in San Francisco, May 18-22. [More]
Roundup: Battles in five states become central to abortion fight; Calif. prison spending on anti-psychotics raises treatment questions

Roundup: Battles in five states become central to abortion fight; Calif. prison spending on anti-psychotics raises treatment questions

Five states have moved to adopt tighter abortion regulations, including North Dakota, where a new law prohibits abortions as soon as a fetal heartbeat is detected. Jeffrey Brown gets perspectives from Charmaine Yoest of Americans United for Life and Ilyse Hogue of NARAL Pro-Choice America (4/30). [More]
1 in 4 teens misused or abused a prescription drug at least once in their lifetime

1 in 4 teens misused or abused a prescription drug at least once in their lifetime

New, nationally projectable survey results released today by The Partnership at Drugfree.org and MetLife Foundation confirmed that one in four teens has misused or abused a prescription (Rx) drug at least once in their lifetime - a 33 percent increase over the past five years. [More]
FDA approves Teva’s generic Adderall XR ANDA for treatment of ADHD

FDA approves Teva’s generic Adderall XR ANDA for treatment of ADHD

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for the generic version of Shire's Adderall XR Capsules, 5mg, 10mg, 15mg, 20mg, 25mg and 30 mg capsules for the treatment of attention deficit hyperactivity disorder. [More]

Shire, Impax resolve pending generic Adderall XR litigation

Impax Laboratories, Inc. today announced that it has settled all pending litigation with Shire LLC and Shire Laboratories, Inc. relating to supply of its authorized generic Adderall XR under the parties' License and Distribution Agreement that was signed in January 2006. [More]
Shire commences ABH001 Phase 3 study in Epidermolysis Bullosa

Shire commences ABH001 Phase 3 study in Epidermolysis Bullosa

Shire plc, today announced the initiation of a Phase 3 study designed to evaluate the efficacy and safety of ABH001, its dermal substitute therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a group of rare genetic skin disorders that begin to manifest at birth or early childhood and occur in approximately 19 per 1 million live births in the US. [More]
NIDA's 2012 Monitoring the Future survey shows rates stable or down for most drugs

NIDA's 2012 Monitoring the Future survey shows rates stable or down for most drugs

Continued high use of marijuana by the nation's eighth, 10th and 12th graders combined with a drop in perceptions of its potential harms was revealed in this year's Monitoring the Future survey, an annual survey of eighth, 10th, and 12th-graders conducted by researchers at the University of Michigan. [More]
First Edition: October 11, 2012

First Edition: October 11, 2012

Today's headlines include previews of how Medicare and other health policy issues might playin tonight's vice presidential debate. [More]
FDA approves Actavis Mixed Amphetamine Salts ER Capsules

FDA approves Actavis Mixed Amphetamine Salts ER Capsules

Actavis Group, an international generic pharmaceuticals company, today announced that it has received approval from the US Food & Drug Administration to market Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended-Release Capsules CII, (hereafter referred to as Mixed Amphetamine Salts ER Capsules), in all available strengths: 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg. [More]
Longer looks: Battling HIV in Washington; Adderall use among U.S. high schoolers

Longer looks: Battling HIV in Washington; Adderall use among U.S. high schoolers

On a recent day not far from Capitol Hill and the White House, about a dozen HIV outreach workers toting bright yellow duffle bags stuffed with condoms and prevention information stood outside of the Anacostia Metro station. ... After a couple of hours, they had handed out hundreds of packs of condoms -- and had persuaded 21 people to take an HIV test with an oral swab in a Chevy van parked nearby. "You have to know your status, man. I'd rather be safe than sorry," said Alvern Harris, 25, as he waited for his results. [More]
Viewpoints: Hoping that 'Gang of Six' will cut fiscal deal; Sen. Alexander links health law and college tuition increases

Viewpoints: Hoping that 'Gang of Six' will cut fiscal deal; Sen. Alexander links health law and college tuition increases

The public has a famously low opinion of Congress, even though people tend to hold a less disparaging view of their own representatives. The last two years have been especially tough on the institution's reputation, a response to the body's relentless brinkmanship and paralyzing partisanship in the face of a slow economy. So it is with some trepidation that I throw out a little love for a handful of senators still seeking bipartisan agreement on a plan to bring the federal government back to fiscal responsibility. [More]

Pisgah receives USPTO Notice of Allowance for drug abuse solution

Pisgah Laboratories, Inc. received Notice of Allowance from the United States Patent and Trademark Office for its patent application entitled "Opioid Salts and Formulations Exhibiting Anti-Abuse and Anti-Dose Dumping Properties." [More]
With Adderall shortage, drug counterfeiters try to seize a market opportunity

With Adderall shortage, drug counterfeiters try to seize a market opportunity

A shortage of Adderall began last year, sending millions of people with attention deficit/hyperactivity disorder and narcolepsy on perpetual wild goose chases to find drugstores with the pills they need to stay alert and focused. So it's not surprising that Adderall counterfeiters have seized a big marketing opportunity. What is surprising is their clumsiness. [More]
Supernus secures $42M through two transactions

Supernus secures $42M through two transactions

Supernus Pharmaceuticals, Inc. today announced that in December 2011 it closed two transactions through which it raised $42 million. [More]
FDA notes shortage of ADHD medicines

FDA notes shortage of ADHD medicines

According to the U.S. Food and Drug Administration (FDA) drugs to treat attention deficit hyperactivity disorder (ADHD) are in such short supply that hundreds of patients complain daily to the agency that they are unable to find a pharmacy with enough pills to fill their prescriptions. [More]
Advertisement
Advertisement